Literature DB >> 3979412

In vivo localization of radioiodinated peanut lectin in a murine TA3/Ha mammary carcinoma model.

A Shysh, S M Eu, A A Noujaim, M R Suresh, B M Longenecker.   

Abstract

Peanut lectin (PNA) binds avidly to oligosaccharides containing the terminal sequence beta-D-Gal(1----3)alpha-D-GAlNAc. This disaccharide is the immunodeterminant group of the Thomsen-Friedenreich (T) antigen which is present in an exposed form on a number of human and animal adenocarcinomas and can be identified in tumor tissue sections by histochemical PNA staining techniques. We have studied the in vivo uptake of radioiodinated PNA in a murine TA3/Ha mammary adenocarcinoma model to evaluate the potential applications of radiolabeled PNA for the immunodetection of T antigen expressing carcinoma. We have found that PNA has a high in vitro binding affinity for the TA3/Ha tumor cells as well as for epiglycanin, a glycoprotein fraction shed by the TA3/Ha cells. Tissue biodistribution studies after IV 125I-PNA injection into TA3/Ha tumor-bearing mice indicated tumor:blood ratios of 7:1 and 55:1 at 24 and 48 h with corresponding tumor:muscle ratios of 33:1 and 77:1. The high tumor uptake and rapid blood clearance allowed clear scintigraphic delineation of tumor by 24 and 48 h without the necessity for background subtraction techniques. Rapid in vivo deiodination of 125I-PNA also contributed to localization of radioactivity in the stomach, salivary glands, thyroid, and kidney.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3979412     DOI: 10.1007/bf00261767

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  41 in total

1.  Chemical structure of epiglycanin, the major glycoprotein of the TA3-Ha ascites cell. The carbohydrate chains.

Authors:  D H Van den Eijnden; N A Evans; J F Codington; V Reinhold; C Silber; R W Jeanloz
Journal:  J Biol Chem       Date:  1979-12-10       Impact factor: 5.157

2.  Blood group MN antigens and precursors in normal and malignant human breast glandular tissue.

Authors:  G F Springer; P R Desai; I Banatwala
Journal:  J Natl Cancer Inst       Date:  1975-02       Impact factor: 13.506

3.  Transplantability and antigenicity of two sublines of the TA3 tumor.

Authors:  B H Sanford; J F Codington; R W Jeanloz; P D Palmer
Journal:  J Immunol       Date:  1973-05       Impact factor: 5.422

4.  Cell-surface glycoproteins of two sublines of the TA3 tumor.

Authors:  J F Codington; B H Sanford; R W Jeanloz
Journal:  J Natl Cancer Inst       Date:  1973-08       Impact factor: 13.506

5.  A monoclonal antibody specific for the Thomsen-Friedenreich cryptic T antigen.

Authors:  A F Rahman; B M Longenecker
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

6.  Histochemical methods for the demonstration of Thomsen-Friedenreich antigen in cell suspensions and tissue sections.

Authors:  P J Klein; R A Newman; P Müller; G Uhlenbruck; H E Schaefer; K J Lennartz; R Fischer
Journal:  Klin Wochenschr       Date:  1978-08-01

7.  Interaction of peanut agglutinin with normal human lymphocytes and with leukemic cells.

Authors:  Y Reisner; M Biniaminov; E Rosenthal; N Sharon; B Ramot
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

8.  Discrete Distribution of binding sites for Dolichos biflorus agglutinin (DBA) and for peanut agglutinin (PNA) in mouse organ tissues.

Authors:  M Watanabe; T Muramatsu; H Shirane; K Ugai
Journal:  J Histochem Cytochem       Date:  1981-07       Impact factor: 2.479

9.  Peanut lectin: a useful tool for detecting Hodgkin cells in paraffin sections.

Authors:  P Möller
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982-08

10.  Biological effects of Corynebacterium parvum. 3. Amplification of resistance and impairment of active immunity to murine tumours.

Authors:  S E Smith; M T Scott
Journal:  Br J Cancer       Date:  1972-10       Impact factor: 7.640

View more
  8 in total

1.  Tumor immunolocalization using 124 I-iodine-labeled JAA-F11 antibody to Thomsen-Friedenreich alpha-linked antigen.

Authors:  Richa Chaturvedi; Jamie Heimburg; Jun Yan; Stephen Koury; Munawwar Sajjad; Hani H Abdel-Nabi; Kate Rittenhouse-Olson
Journal:  Appl Radiat Isot       Date:  2007-08-17       Impact factor: 1.513

Review 2.  Cancer vaccines and carbohydrate epitopes.

Authors:  Jamie Heimburg-Molinaro; Michelle Lum; Geraldine Vijay; Miten Jain; Adel Almogren; Kate Rittenhouse-Olson
Journal:  Vaccine       Date:  2011-10-01       Impact factor: 3.641

Review 3.  The application of lectins to the characterization and isolation of mammalian cell populations.

Authors:  J P McCoy
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

4.  Biodistribution of neoglycoproteins in mice bearing solid Ehrlich tumor.

Authors:  S Kojima; H J Gabius
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

5.  Comparisons of labeling efficiency, biological activity and biodistribution among 125I-, 67Ga-DTPA-and 67Ga-DFO-lectins.

Authors:  S Kojima; M Jay
Journal:  Eur J Nucl Med       Date:  1987

6.  An experimental study on differential diagnosis of tumor from inflammation by using 125I labeled Pisum sativum agglutinin.

Authors:  S Kojima; M Jay
Journal:  Eur J Nucl Med       Date:  1987

7.  Radioiodinated peanut lectin: clinical use as a tumour-imaging agent and potential use in assessing renal-tubular function.

Authors:  E A Abdi; V J Kamitomo; T A McPherson; Z Catz; G Boniface; B M Longenecker; A A Noujaim
Journal:  Eur J Nucl Med       Date:  1986

8.  Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis.

Authors:  Swetha Tati; John C Fisk; Julia Abdullah; Loukia Karacosta; Taylor Chrisikos; Padraic Philbin; Susan Morey; Diala Ghazal; Fatma Zazala; Joseph Jessee; Sally Quataert; Stephen Koury; David Moreno; Jing Ying Eng; Vladislav V Glinsky; Olga V Glinskii; Muctarr Sesay; Anthony W Gebhard; Karamveer Birthare; James R Olson; Kate Rittenhouse-Olson
Journal:  Neoplasia       Date:  2017-08-19       Impact factor: 5.715

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.